A series of carbamides derived from 1,2:5,6-di-O-isopropylidene-D-gluco-(1) and D-allofuranose (3) as well as their 5,6-O-deprotected analogues (2 and 4) and methyl 3,4-O-isopropylidene-α-and β-D-galactopyranosides (5 and 6) have been prepared in order to evaluate their ability to induce erythroid differentiation of human erythroleukemic K562 cells. Twenty out of the 51 carbamides tested exhibit an appreciable activity as inducers of erythroid differentiation and have been fully characterised and described.
Introduction
The K562 cell line, isolated and characterized by Lozzio and Lozzio 1 from a patient with chronic myelogenous leukemia in blast crisis, has been proposed as a very useful experimental model system to identify inducers of γ-globin gene expression of possible interest in the therapy of several haematological diseases, including β-thalassemia and sickle cell anaemia. 2 K562 cells exhibit a low proportion of hemoglobin-synthetizing cells under standard cell growth conditions, but are able to undergo erythroid differentiation when treated with a variety of compounds, including short fatty acids, 5-azacytidine, mithramycin, and chromomycin, cisplatin and cisplatin analogues, tallimustine, rapamycin, everolimus, psoralens and resveratrol.
esters have been initially proposed merely as convenient prodrugs, able to gradually release the pharmacophore following the in vivo action of esterases. 8 In recent papers regarding the synthesis and evaluation of some partially acetonated monosaccharide esters of several fatty acids we have highlighted the role of the structure of either the ester and the carbohydrate residue in the antiproliferative effects and erythroid differentiation activity of K562 cells. 9 Furthermore, it was observed that some glycose isobutyrates and pivaloates stimulate erythroid differentiation to higher levels than the corresponding free fatty acids. 9 Consequently, we assumed that, at least in the case of isobutyrates and pivaloates, the biological activity of monosaccharide esters might be related to the whole structure prior to the occurrence of the hydrolysis takes place, rather than to the release of the free fatty acid acting as biologically active component.
Unfortunately, fast in vivo ester hydrolysis on rabbit 10 precludes the possibility of any therapeutic use of glycide esters. Therefore, we turned our efforts to investigate some more stable isosters of active glycose esters. Among various possibilities, we decided to focus on the substitution of the ester group with an amide one, which would offer the advantage of a simple synthetic access.
The present paper deals with the synthesis and the biological evaluation of part of a library of glycose carbamides 1-6 (chart 1) in which the carbohydrate scaffoldings where the same of the previously described biologically active glycide esters. 9 Besides butyrates and pivaloates, we have selected a wide set of acyl residues classified into three groups (Chart 1): the first one includes linear and branched fatty acids (group A), the second one contains residues characterized by the presence of aromatic or heteroaromatic rings (group B) and the third one is a miscellaneous group (group C) including residues with heteroatoms or unsaturations within the chain.
A subset of 51 compounds, out of 174 glycose carbamides represented in Chart 1, were synthesised and tested towards for biological activity on the K562 cellular system a subset, 20 of them showed an appreciable erythroid differentiation inducing activity on K562 cells. Synthesis, characterization and ability to induce erythroid differentiation of these biologically active compounds are herein presented. were prepared according to literature procedures. The synthesis of methyl α-and β-6-amino-6- The glycose carbamide of type 1, 3, 5 and 6 were prepared through parallel synthesis by treatment of the four aminated scaffolds 7, 8, 15 and 16 with an excess of the appropriate commercial acyl chlorides in methylene chloride in the presence of PS-piperidinomethyl resin (Scheme 2).
Partially protected furanosic carbamides of type 2 and 4 (scheme 1) were obtained from protected ones (1 and 3) through selective hydrolytic removal of 5,6 acetonide group with 80% aqueous AcOH. In the case of the D-allose series (3) acid hydrolysis was conducted under milder temperature conditions (45 °C) with respect to that used for D-glucose analogues (60 °C), in order to prevent complete removal of the two acetal groups. As pointed out by Collins, 16 in fact, the hydrolysis rate of the 1,2-O-isopropylidene functionality in the D-allose series is higher with respect to that observed for analogous acetonide functionality in the D-glucose series. 16 All the compounds were fully characterized by 
Biological activity
The human leukemia K562 cell line 17 was kept in a humidified atmosphere of 5% CO 2 /air in RPMI 1640 medium (Sigma, St. Louis, MO, USA) supplemented with 10% fetal bovine serum (FBS; celbio, MI, Italy), 50 Units/mL penicillin and 50 µg/mL streptomycin. 18 In order to determine the ability of the tested compounds to inhibit the cell growth and induce the erythroid differentiation, K562 cells (30,000 cells/mL) were cultured both in the absence and in the presence of the indicated concentrations of compounds and the cell number/mL determined with a ZF Coulter Counter Among the tested carbamides (1Ca, 1Ac, 1Al, 2Aa, 2Ab, 2Ac, 2Ad, 2Ae, 2Af, 2Ag, 2Ah, 2Ai, 2Aj, 2Ak, 2Am, 2An, 2Ao, 2Be, 2Ca, 2Cb, 3Ab, 3Ad, 3Af, 3Ah, 3Al, 3An, 3Ba, 3Bb, 3Bc, 3Bd, Results are presented as average ± SD (three independent experiments performed) of % of benzidine-positive (haemoglobin-containing) cells after 6 days induction period at the indicated concentrations of the tested compounds. Sub-optimal concentrations of ara-C (200 nm) were used in combination with the tested compounds.
When the analysis of the structure of carbamides active in the stimulation of erythroid differentiation was performed, it was found that seven of those exhibited linear saturated fatty acid residues, three branched saturated fatty acid residues and two alicyclic residues. However, we underline that many amides of linear, branched and most of alicyclic fatty acid residue are present
in the list of inactive tested amide (i.e. 2Ak, 3Af, 5Ac, 2An). In addition, it should be note that, In conclusion, the majority of active glycose carbamides act with a mechanism resembling ara-C (no synergism observed with ara-C); three carbamides (2Ac, 4Ac and 4Aj) display a mechanism of action presumably different compared to that exhibited by sub-optimal concentrations of ara-C; six (2Aj, 3Bf, 3Bb, 3Bd, 4Ai and 4Bh), which are not active by themselves, are however able to enhance ara-C mediated erythroid induction. Whether they induce a part of the erythroid differentiation program complementary to that stimulated by sub-optimal concentrations of ara-C remains to be investigated.
As far as structure-activity relationship (SAR) analysis, we like to underline that compounds of type 2 display the highest probability (35% in our set) to induce differentiation (6/17, compared to 2/15 and 3/13 of compounds of type 3 and 4, respectively). Compounds carrying residues of group A display the highest probability (36%) to induce erythroid differentiation (11/31, compared to 1/14 and 1/6 of compounds carrying residues of group B and C, respectively).
More in detail, all the compounds carrying the residue Ab (R = CH 2 CH 3 ) and three out of five compounds carrying residue Ac [R = (CH 2 ) 2 CH 3 ] were found able to induce differentiation (two of them, 2Ac and 4Ac, also in synergism with ara-C). With respect to synergism with ara-C, only the compounds carrying the residue R = C(CH 3 ) 3 (2Aj and 4Aj)were found to be active in inducing high level of differentiation.
Despite being limited, this SAR analysis suggest that the most promising molecules able to induce differentiation are glycose carbamides of type 2 or those displaying residues Ab (R = CH 2 CH 3 ) and
) 3 ] appears to be involved in the property to act in synergism with ara-C. Obviously, this hypothesis is not conclusive, due to our choice of a diversity oriented selection of compounds within the complete library of carbamides. This choice has allowed to explore some representative of each class of acyl residue, but it has prevented the performance of a systematic sight on the effect of glycide scaffold in biological activity when a same acyl residue is considered. The SAR analysis here discussed should be considered a starting point for further synthetic activity toward the generation of other oriented set of analogues, thus helping to verify this hypothesis.
Experimental section

General methods
Melting points were determined with a Kofler hot-stage apparatus and are uncorrected. Optical rotations were measured on a Perkin-Elmer 241 polarimeter at 20 ± 2 °C. PS-piperidinomethyl resin and polyamine resin were purchased from Novabiochem. 
Amino scaffolds
3-Ammino-3-deoxy-1,2:5,6-di-O-isopropylidene-α-D-glucofuranose
Methyl-3,4-O-isopropylidene-6-O-methylsulphonyl-α-D-galactopyranoside (11)
A solution of 9
13
(1.00 g, 4.27 mmol) in pyridine (25 mL) was treated at 0 °C under stirring with commercial methylsulphoyl chloride (896 mg, 4.70 mmol). The solution was allowed to warm to room temperature and stirred until the TLC analysis (EtOAc) showed the complete disappearance of the starting material (74 h) and the formation of one component (R f 0.51). 
Methyl-3,4-O-isopropylidene-6-O-methylsulphonyl-β-D-galactopyranoside (12)
This compound was prepared starting from 10 
Methyl-6-azido-6-deoxy-3,4-O-isopropylidene-α-D-galactopyranoside (13)
A solution of 11 (1.00 g, 2.58 mmol) in DMF and (35 mL) was treated with commercial sodium 
Methyl-6-azido-6-deoxy-3,4-O-isopropylidene-β-D-galactopyranoside (14)
This compound was prepared starting from 12 (1.50 g, 3.87 mmol) by a procedure analogous to that of 13. White solid, 792 mg (79% 
Methyl-6-amino-6-deoxy-3,4-O-isopropylidene-α-D-galactopyranoside (15)
To a suspension of LiAlH 4 (93 mg, 2. 
Methyl-6-amino-6-deoxy-3,4-O-isopropylidene-β-D-galactopyranoside (16)
General method for the parallel synthesis of amides of type 1, 3, 5 and 6
A 0.2 M solution of amine scaffold in CH 2 Cl 2 and a 0.4 M solution of the selected acyl chloride in CH 2 Cl 2 where prepared under anhydrous conditions.
In each reactor 1.00 g of resin PS-piperidinomethyl was put and in sequence 5 mL of the solution containing the amine and 5 mL of the solution containing the acyl chloride were added. The reaction mixture was stirred a room temperature for 12 hours. The reaction proceeding was checked by HPLC-MS. A 1.00 g of resin polyamine (loading = 3.2 mmol/g) to extract the excess the acyl chloride was added after dilution with CH 2 Cl 2 (5 mL) and vortically stirred for two hours. The suspension were filtered on paper and the clear solutions were evaporated under diminished pressure to give oils that were purified by a Combi Flash chromatographic system (ISCO, using columns Redisep of 10 g eluting with a CH 2 Cl 2 -MeOH gradient from 98:2 to 95:5. After evaporation of the solvent pure products were obtained.
General method of the synthesis of selectively deprotected furanosic amides of type 1 and 3
The fully protected amides of type 1 and 3 (1.5-3.0 mmol), prepared following the general procedure reported above, were dissolved in 80% aqueous AcOH (20 mL) and the resulting 
Active carbamides 4.5.1. 3-N-(2-Butynoyl)-3-deoxy-1,2:5,6-di-O-isopropylidene-α-D-glucofuranose (1Ca
3-N-Propanoyl-3-deoxy-1,2-O-isopropylidene-α-D-glucofuranose (2Ab
3-N-Butanoyl-3-deoxy-1,2-O-isopropylidene-α-D-glucofuranose (2Ac
3-N-Pentanoyl-3-deoxy-1,2-O-isopropylidene-α-D-glucofuranose (2Ad).
3-N-hexanoyl-3-deoxy-1,2-O-isopropylidene-α-D-glucofuranose (2Ae
3-N-(3-Methylbutanoyl-3-deoxy-5,6-O-isopropylidene-α-D-glucofuranose (2Af
3-N-(3,3-Dimethylbutanoyl)-3-deoxy-1,2-O-isopropylidene-α-D-glucofuranose (2Ah). From 7
(778 mg, 3.00 mmol) by acylation with 3,3-dimethylbutanoyl chloride and subsequent hydrolysis; 
3-N-Pivaloyl-3-deoxy-1,2-O-isopropylidene-α-D-glucofuranose (2Aj)
.
3-N-Propanoyl-3-deoxy-1,2:5,6-di-O-isopropylidene-α-D-allofuranose (3Ab
3-N-(3-Methoxyphenylacetyl)-3-deoxy-1,2:3,4-di-O-isopropylidene-α-D-allofuranose (3Bb).
From 8 Table 6 
3-N-(2,5-Dimethoxyphenylacetyl)-3-deoxy-1,2:3,4-di-O-isopropylidene-α-D-allofuranose (3Bd
3-N-Hydrocinnammoyl-3-deoxy-1,2:3,4-di-O-isopropylidene-α-D-allofuranose (3Bf
3-N-(Biphenyl-4-carbonyl)-3-deoxy-1,2-O-isopropylidene-α-D-allofuranose (4Bh
3-N-(4-Methoxybenzoyl)-3-deoxy-1,2-O-isopropylidene-α-D-allofuranose (4Bi)
Methyl-6-N-butanoyl-6-deoxy-3,4-O-isopropylidene-α-D-galactopyranoside (5Ac
